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3THESIS AT A GLANCE
STUDY AIMS MAIN RESULTS
I
To assess the combined
sum of glucose and lactate
as an indicator of
glycemic control.
The combined sum of
glucose and lactate may
refer to glycemic
disturbances. Additional
markers are needed for
more precise estimation of
antemortem (AM)
glycemic state
II
To estimate and optimize
the methods for
measurement of glycated
hemoglobin (HbA1c) in
postmortem (PM) samples
and to assess the
information provided by
the analysis.
Chromatographic method
is optimal as the PM
changes can be visualized
and false results avoided.
HbA1c is fairly stable if
preserved in EDTA-tubes.
HbA1c is significant
when assessing the AM
glycemic balance.
III
To evaluate ketone body
levels in deaths attributed
to diabetes and alcohol
abuse and to evaluate the
most appropriate analysis
method to determine
ketoacidosis
Ketone body levels are
often higher in diabetes
related deaths than in
alcohol related deaths, but
additional markers need to
be analyzed to distinguish
the cause for ketoacidosis.
Acetone alone is not
sufficient to detect
ketoacidosis; either total
ketones or beta-hydroxy
butyrate need to be
analyzed.
IV
To measure C-reactive
protein (CRP) in PM
samples and to assess the
role of CRP in
ketoacidosis
CRP was very stable after
sampling and the CRP
levels of PM samples
were approximately 40%
of the AM samples.
Alcoholic ketoacidosis
may elevate CRP levels.
V
To evaluate different AM
and PM factors that
influence the lactate levels
in PM samples and to
estimate the role of
elevated lactate in diabetes
related deaths
Lactate levels elevate in a
logarithmic manner as
PMI increases mainly due
to microbial metabolism.
Lactate levels are
relatively higher in
diabetes type 2 related
deaths implicating AM
metabolic disturbances.
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6ABBREVIATIONS
1,5- AG 1,5-anhydroglucitol
AcAc acetoacetate
AGE advanced glycated end product
AKA alcoholic ketoacidosis
AM antemortem
AUD alcohol use disorder
BHB beta-hydroxy butyrate
BHBD beta-hydroxy butyrate dehydrogenase
CF cerebrospinal fluid
CRP c-reactive protein
CoA coenzyme A
CoD cause of death
G6P glucose 6-phosphate
GC gas chromatography
DKA diabetic ketoacidosis
DM diabetes mellitus
DM1 diabetes mellitus type I
DM2 diabetes mellitus type II
EDTA ethylenediaminetetraacetic acid
HbA1c glycated hemoglobin
HHS hyperglycemic hyperosmolar state
INT iodonitrotetrazolium
KPDM2 ketosis-prone diabetes mellitus type II
LDH lactate dehydrogenase
MeG methylglyoxal
NADH/NAD+ nicotinamide adenine dinucleotide
NaF sodium fluoride
PCA perchloric acid
PF pericardial fluid
PM postmortem
PMI postmortem interval
RI reference interval
VH vitreous humor
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8ABSTRACT
Postmortem (PM) biochemistry is utilized in cause of death (CoD) investigations. The challenges
in PM biochemistry are caused mainly by the PM changes. Analytes may be degraded or
denatured leading to methodological difficulties. In addition, the re-distribution may cause falsely
elevated values when compared to clinical samples. Analytes may also be consumed or produced
by microbial metabolism. The sample matrix is often different from that in clinical biochemistry
and the reference levels need be obtained through research. The actual death process and agonal
period can also lead to unique changes in the analyte concentrations. Despite these challenges,
with a sufficient number of samples and adequate research it is possible to optimize biochemical
methods for PM samples and obtain reference values for certain conditions.
The biochemical results can provide supporting information in cases where the death is caused or
associated with metabolic disturbances for instance in diabetes mellitus (DM) or alcohol abuse.
Hyperglycemia and ketoacidosis in diabetes can be fatal if not treated. The macroscopical,
histological and toxicological findings in autopsy may be scarce or even absent. Determination
of vitreous humor (VH) glucose and ketone bodies are very informative in these cases. As
ketoacidosis can be present also after heavy alcohol use, the determination of glycemic status
prior to death is essential in distinguishing between these two conditions. Glycated hemoglobin
(HbA1c) provides information on the glycemic balance in previous weeks.
In our studies, we have assessed the results, methods and interpretation provided by analysis of
glucose, lactate, ketone bodies, HbA1c and C-reactive protein (CRP) in PM samples.
Optimization has been performed in routine casework according to our findings providing more
accurate information to the medico-legal pathologists in their CoD investigation work. In
addition, our results have provided some insights into the pathology of severe diabetic
emergencies as well as to ketoacidosis due to alcohol.
According to our results, we recommend that in DM and alcohol abuse related deaths VH glucose,
total ketone bodies or beta-hydroxy butyrate and blood HbA1c should always be analyzed.
Lactate levels may provide additional information, when the results are interpreted considering
the PM interval (PMI). These analyses are recommended also in cases where no suspicion of
metabolic disturbances exists, but the findings in autopsy are scarce.
The collaboration between the medico-legal pathologists and the laboratory is very important for
the development and understanding of PM biochemistry and to include novel analyses to support
the CoD investigation. The CoD determination is very important not only on the individual level,
but also nationally, since Finnish Statistics collects the CoD data, which can be than further
utilized in recommendations concerning health and primary prevention.
9INTRODUCTION
Forensic biochemistry can be defined as “the study of the biochemical parameters in the cadaver,
to solve the problems that outline the diagnosis of the cause and circumstances of the death” [1].
Coe et al. have described a comprehensive range of different biochemical analytes that can be
useful in forensic medicine [2]. These and others have been utilized in cause of death (CoD)
investigations or in postmortem (PM) research concerning for instance evaluation of glycemic
status in suspected diabetic deaths [3-9], sepsis or inflammation [10-15], metabolic disturbances
caused by alcohol abuse [16-19], long term alcohol abuse [20-22],  sudden cardiac deaths [23-
29] and deaths caused by hypo- or hyperthermia [30-34]. In addition to diagnostic purposes,
biochemical markers have been utilized in time of death estimations [35,36].
Despite the various biochemical assays available, PM biochemistry is not very often included as
a routine process in forensic autopsies [37]. The application of biochemical methods for analysis
of PM samples is rarely straightforward [38], which may lead to suspicion about the reliability of
the results. PM changes, such as autolysis and putrefaction, may complicate the analysis and
cause erratic results [39]. The extent of PM changes depends mostly on the PMI, but also on the
antemortem (AM) and PM environmental circumstances and pathological conditions prior to
death [40,41].
Because of PM changes and potential body destruction the sample matrices needed are not always
available. Plasma or serum is often the matrix of choice in clinical biochemistry, whereas PM
samples do not always allow the separation of these from whole blood. Blood is also prone to
alterations caused by bacterial metabolism and autolysis. Therefore, alternative sample matrices
for blood (or plasma/serum), such as the vitreous humor (VH) of the eye, cerebrospinal fluid (CF)
and pericardial fluid (PF), are preferred. If the matrix differs from the one used in clinical
biochemistry, the correlation of the concentrations in different matrices needs to be evaluated.
The distribution of the analyte or biomolecule in tissues and body fluids is relevant. The PM
redistribution is better described in forensic toxicology regarding drugs [42]. It is also relevant in
PM biochemistry if the analyte is for instance a marker of tissue disruption such as the liver
enzymes, alanine aminotransferase and aspartate aminotransferase [43], when autolysis greatly
influences the concentration in blood.
Also the interpretation of PM results often differs compared to clinical biochemistry. The
reference intervals (RIs) of clinical assays are usually set so that 95 % of healthy individuals are
within the reference range [44]. No public databases for PM biochemical RIs exist, so each
laboratory needs to set their own based on the particular sample material that is analyzed and the
methods that are used in the unit [45]. RIs need to be set so that in addition to the population and
the method used, the effects of PM changes are taken into account. In addition, the purpose of the
analysis should be addressed; for example is it relevant to know any slight changes in blood
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glucose, or is the aim only to find cases where the glycemic control is so unbalanced that the
condition may be fatal?
The PM changes cause difficulties in analyzing samples as well as the interpretation of the results.
In addition, there are different opinions on which markers are the relevant ones to support the
diagnosis of the CoD.  Therefore, a suitable combination of metabolic markers is needed [6,8].
The challenges of PM biochemistry can be addressed by research and co-operation between the
laboratory and forensic pathologists performing the autopsies. By using a multidisciplinary
approach, the most suitable combination of biochemical markers can be found providing essential
information for the CoD investigation [37].
This thesis focuses on metabolic acidosis in diabetes and alcohol abuse caused by elevated ketone
bodies, lactate or both. Glycemic disturbances in diabetes mellitus (DM) are also addressed. The
preferable combination of metabolites to be analyzed, the analysis methods and interpretation of
results are presented and discussed.
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REVIEW OF THE LITERATURE
1. Derangements in carbohydrate metabolism causing acidosis
In the normal physiological state, glucose is used as a source of energy in the cells or it can be
stored in the form of glycogen in the liver and skeletal muscle cells when energy is abundant [46].
In DM the glucose metabolism is impaired causing hyperglycemia if not treated. Ketoacidosis
can result if fats are used for energy in the absence of intracellular glucose [47]. Another cause
for ketoacidosis and possible concomitant lactic acidosis is long-term alcohol abuse [48]. These
derangements are often severe and can be fatal when untreated.
1.1 Diabetes and its acute complications
DM is a range of metabolic diseases, where the secretion or the effect of insulin is insufficient
leading to elevated blood glucose [49,50]. Most of the patients belong to either type 1 diabetes
(DM1) or type 2 diabetes (DM2). Other categories of diabetes include gestational diabetes and
other specific types caused for instance by genetic defects in insulin secretion or action, diseases
of the exocrine pancreas, endocrinopathies, drugs or chemicals and infections [50,51].  In DM1
the insulin deficiency is caused by the autoimmune destruction of the -cells in the pancreas and
subsequent lack of excretion [52], whereas in DM2 the effect of insulin is diminished causing
relative deficiency [53]. Consistently elevated blood glucose in DM causes several macro- and
microvascular complications, such as retinopathy [54], neuropathy [55] and cardiovascular
disease [56,57].
Acute complications of diabetes or its treatment are hypoglycemia [58], diabetic ketoacidosis
(DKA) and hyperglycemic hyperosmolar state (HHS) [59-61]. Severe hypoglycemia is diagnosed
when 1) blood glucose is less than 3.9 mM, the symptoms are typical to hypoglycemia and they
are resolved after glucose administration and 2) there is a need for medical or non-medical
external help [58]. DKA results from inadequate insulin amount or effect and the increased action
of counterregulatory hormones (glucagon, growth hormone, catecholamines and cortisol) that
lead to hyperglycemia and ketoacidosis [60]. HHS is caused by the same factors as DKA. The
differences between these are that in HHS the dehydration is greater than in DKA, but insulin
secretion is not as diminished preventing ketosis [62]. Typical diagnostic laboratory findings in
DKA and HHS are presented in Table 1 [60].
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Table 1. Clinical laboratory findings in diabetic ketoacidosis (DKA) and the hyperglycemic
hyperosmolar state (HHS)
Severe DKA HHS
Plasma glucose (mM) >14 >33
Arterial pH < 7 >7.30
Serum bicarbonate (mM) < 10 > 15
Urine/Serum ketones positive small
Serum osmolality (mOsm/kg) variable > 320
Anion gap (mM) > 12 < 12
1.2 Alcohol abuse and metabolic disturbances
Alcohol abuse and dependence predict markedly elevated risk of mortality [63]. In a recent study
by Westman et al. it was found that mortality among patients suffering from alcohol use disorder
(AUD) was significantly higher than in the general populations in Finland, Sweden and Denmark
[64].  The causes for premature deaths were alcohol related diseases and medical conditions,
suicide and other external causes. The bias in their study was that it included only hospitalized
patients with AUD, who are likely to have more severe health issues than patients outside of
medical care. In 2013 in Finland 15% of all deaths of working-age (15-64 years) people were due
to alcohol related diseases and accidental poisoning by alcohol [65]. Alcohol related deaths were
the third most common CoD in this age group, which makes it a significant public health issue.
Common CoD’s due to alcohol are liver diseases, pancreatic diseases, cancer and cardiovascular
diseases [66] in addition to alcohol poisonings [67]. Alcohol is also often a contributing CoD in
accidents [67].
In addition to idiopathic, autoimmune and genetic factors, also alcohol may cause acute and
chronic pancreatitis [68,69]. The acute form can further evolve to the chronic form after recurrent
episodes [70]. Chronic pancreatitis is the cause in almost 80% of the cases of secondary diabetes
due to pancreatic diseases (type 3c diabetes; DM3c) [71]. The impairment of glucose metabolism
in DM3c is variable from mild to severe and the condition is complex due to the destruction of
exocrine and glucagon producing cells in addition to insulin producing cells causing a “brittle”
disease, in which the glycemic balance is difficult to sustain [71,72]. These large swings in blood
glucose level predispose individuals to the acute metabolic emergencies of DM.
Alcohol abuse can cause metabolic disturbances that are not related to DM, although the
manifestations are similar [73]. Ketoacidosis in non-diabetic adults after prolonged alcohol
consumption was first described by Dillon et al. in 1940 [74]. This syndrome was later defined
as alcoholic ketoacidosis (AKA) by Jenkins et al. [75]. It is typically presented after binge
drinking and poor nutrition, and may be worsened with concomitant lactic acidosis [76]. In
addition to AKA and lactic acidosis [77], heavy alcohol use may cause severe hypoglycemia [78].
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1.3 Formation of ketone bodies and ketoacidosis
Ketone bodies are formed in the liver as a result of fatty acid oxidation in low carbohydrate
conditions. Normally, fatty acids and glucose are metabolized to acetyl coenzyme A (acetyl
CoA), which enters the citric acid cycle by condensing with oxaloacetate [79]. If glycolysis is
insufficient the acetyl CoA molecules from fatty acid oxidation are used for ketogenesis. Two
acetyl CoA molecules condense into acetoacetyl CoA, which forms the ketone body acetoacetate
(AcAc) through 3-hydroxy-3-methylglutaryl CoA. AcAc can be further reduced to another ketone
body, beta-hydroxybutyrate (BHB), in nicotineamide adenine dinucleotide (NADH; reduced
form, NAD+; oxidized form) dependent reaction catalyzed by beta- hydroxybutyrate
dehydrogenase (BHBD).  AcAc can also be decarboxylated to form acetone. In ketosis, the excess
acetone may further form isopropyl alcohol in some cases [80,81]. The main components of
ketone body formation are presented in Figure 1.
Figure 1 Sources of ketone bodies; acetyl CoA is formed in glucose or fatty acid metabolism. If
abundant, acetyl CoA is not shuttled into the citric acid cycle but instead forms acetoacetate.
Common causes for ketoacidosis are diabetes, alcohol abuse and starvation. In DKA the
deficiency of insulin impairs the carbon hydrate metabolism, which in turn leads to
hyperglycemia followed by lipolysis and ketogenesis induced by counterregulatory hormones,
such as glucagon, cortisol, growth hormone and catecholamines. DKA was thought to be
associated mainly with DM1 and it occurred only rarely in DM2 during acute illness where the
counterregulatory hormones are elevated. Later it has been found that ketoacidosis is also often
associated with DM2 [82,83]. In addition, in a subtype of diabetes called ketosis-prone type 2
diabetes (KPDM2), DKA may occur without the precipitating factors.  KPDM2 was originally
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found among African-Americans, but later also in several other populations [84].  Linfoot et al.
[85] compared DM2 and KPDM2 groups and found that the hormonal levels in both groups were
similar. They suggested that ketoacidosis in KPDM2 is caused by impaired insulin secretion that
can be resolved later during treatment.
The elevation of ketones after heavy alcohol consumption is caused primarily by an elevated
NADH/NAD+ ratio [86,87]. The metabolism of alcohol and following elevated NADH/NAD+
ratio reduce gluconeogenesis and aerobic oxidation in the citric acid cycle. Counterregulatory
hormones induce lipolysis and fatty acid oxidation and the production of acetyl CoA. The blood
glucose level is often normal or even low, especially if the prolonged alcohol abuse is associated
with malnourishment and the glycogen storages are depleted [76,88,89]. In addition to an elevated
NADH/ NAD+ ratio, excess acetate is formed in alcohol metabolism. Acetate could serve as a
precursor for ketone bodies as presented in Figure 2, although there have been some controversial
findings about this. For instance, Yamashita et al. concluded in their in vitro study that although
acetate is formed in the liver due to alcohol metabolism, it is not further metabolized, but utilized
in peripheral tissues [90].
Figure 2 Formation of ketone bodies in alcoholic ketoacidosis; enhanced lipolysis and possibly
the acetate from alcohol metabolism form excess acetyl CoA, which further forms acetoacetate.
In diabetes care the method for ketone testing has traditionally been a test based on the reaction
of AcAc in urine or blood in the presence of alkali with nitroprusside (nitroferricyanide) to
produce a colored complex [86]. As this method relies on the AcAc concentration and not the
more predominating BHB, it is not as sensitive a marker in DKA as BHB [91]. The recommended
assay in DM for ketones is therefore a test that quantifies blood BHB [92]. In AKA the
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BHB/AcAc ratio is even higher than in DKA [93], which would suggest that BHB is the optimal
marker for ketoacidosis.
1.4 Lactic acidosis in diabetes and alcohol abuse
Lactate is produced in glycolysis from pyruvate under anaerobic conditions. Pyruvate is reduced
by lactate dehydrogenase (LDH) and the cofactor NADH is oxidized to NAD+. Normally most
of the pyruvate is transformed into acetyl CoA, which enters the citric acid cycle. An elevation
of NADH/NAD+ ratio and the accumulation of pyruvate favor the formation of lactate. Lactate is
converted back to pyruvate in the liver or kidneys and used for the formation of glucose in the
Cori cycle [94]. Small amounts can be excreted in urine. Lactic acidosis occurs if the production
of lactate exceeds its utilization. Cohen and Woods [95] classified lactic acidosis into two
subtypes A and B. Type A lactic acidosis is caused by insufficient oxygen delivery and type B
by inadequate utilization of oxygen e.g. in diabetes, the systemic inflammatory response
syndrome (SIRS), mitochondrial myopathies, malignancy and in some intoxications [96].
Lactic acidosis in DM2 has been thought to be associated with the biguanides (phenformin and
metformin) used in the therapy of diabetes. Phenformin was withdrawn as it caused severe lactic
acidosis [97], and since metformin belongs to the same drug class it has also raised questions
about the safety of the treatment [98]. However, a systematic Cochrane review by Salpeter et al.
[99] stated that the incidence of lactic acidosis is similar with the metformin treated patients and
patients treated with other anti-hyperglycemic medications. Therefore, the lactic acidosis may
rather be coincidental due to other precipitating causes then metformin medication [100,101].
As ethanol metabolism elevates the NADH/NAD+ ratio (Figure 2) the conversion of pyruvate to
lactate is enhanced and may lead to lactic acidosis in alcoholics. If the alcohol abuse has caused
malnourishment, an additional risk for lactic acidosis exists due to thiamine deficiency [102].
Thiamine is an essential cofactor for several enzymes and its deficiency leads to impaired aerobic
glucose metabolism and subsequent lactic acidosis [103].
1.5 D-lactate in diabetes
Under normal conditions, lactate in humans is mainly in the L-isoform and only a small amount
of D-lactate is formed from methyl glyoxal (MeG) in the glyoxalase system in cytosol and cell
organelles, especially mitochondria [104]. D-lactate can also be formed in the bowel as a result
of microbial fermentation. D-lactic acidosis is a rare neurologic syndrome most commonly caused
by malabsorption (e.g. in short bowel syndrome) of relatively large amounts of fermentable
carbohydrates [105,106]. Elevated D-lactate levels have been found also in diabetics due to
hyperglycemia and/or ketoacidosis, which elevate MeG amounts that in turn are metabolized into
D-lactate [107,108]. MeG is a significant factor in diabetic complications, since it is a very
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efficient glycating agent and serves as a precursor for advanced glycated end products (AGEs)
that cause microvascular complications [109]. D-lactate measurements have been evaluated for
assessing the AGE load and also for diagnosis of D-lactic acidosis [110,111]. The evaluation of
D-lactate measurements has not been performed for PM samples.
2. Postmortem analysis of metabolic disturbances
Biochemical markers are informative in deaths due to metabolic disturbances in DM and alcohol
abuse, since these conditions may not be detectable in autopsy by other means. In histological
examination, diabetic nephropathy or fatty liver may be present [112]. Also glycogen containing
cytoplasmic vacuolizations of the renal tubular cells (Armanni-Ebstein lesions) caused by
hyperglycemia can exist. Closely similar basal vacuolizations containing lipids and triglycerides
can be formed in ketoacidosis even without concomitant hyperglycemia [113]. Although
significant, these findings can be more specified by combining the biochemical results of glucose
and fat metabolism [114-117]. Tormey and Moore stated that to identify the role of diabetes in
sudden deaths, biochemical markers should be evaluated routinely [118].
2.1 Evaluation of glycemic balance by analyzing PM samples
VH glucose concentration can be assessed when hyperglycemia prior to death is suspected [119].
Glucose concentration in VH correlates with the (AM) blood glucose levels being approximately
0.4-0.5 times the blood concentration [3,5]. Urine glucose is not the optimal choice, since it is not
necessarily elevated even in moderate hyperglycemia due to individually variable renal threshold
for glucose [6]. VH glucose concentration decreases in the early PM phase. This decrease is
partially caused by anaerobic glycolysis in the hyalocytes [5] where one molecule of glucose
turns into two molecules of lactate. Traub suggested that in estimating AM hyperglycemia the
combined sum of glucose and lactate should be used to include the effect of glycolysis [120].
This value has been commonly used in interpretation of hyperglycemia in PM biochemistry
[3,4,6,121]. However, there have been questions about the reliability of the combined sum.
Factors other than glycolysis can be the source of lactate, such as autolysis, bacterial metabolism,
AM lactic acidosis and prolonged agony prior to death [5,122]. Therefore, the Traub value may
overestimate hyperglycemic deaths and currently glucose alone is preferred as a marker for AM
hyperglycemia [5,112,123].
There is no reliable way to diagnose hypoglycemia by analyzing the glucose concentration of PM
samples [2], since the glucose level decreases after death. To aid in the interpretation of
hypoglycemia it can be more informative to analyze human insulin and its synthetic analogs,
although there are also challenges due to the instability of insulin in hemolyzed PM blood, this is
why the vitreous is preferred [124-126].
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Glycated hemoglobin (HbA1c) is formed as a result of non-enzymatic addition of glucose to
hemoglobin [127]. It is formed after prolonged (~12 hrs.) glucose exposure [128,129] and reflects
the average blood glucose level during the preceding 1-2 months. Because of methodological
variability the results may differ significantly [130], but after successful international
standardization [131,132], HbA1c is recommended as one of the markers for diagnosis and
follow-up of diabetes [133].  The usefulness of HbA1c in PM samples was has already been
assessed over 30 years ago [4,134]. The conclusion of these studies was that HbA1c is a useful
marker and also very stable even in PM samples. Valenzuela concluded in a study of fructosamine
and HbA1c in PM samples that HbA1c measurement is an important advantage in PM diagnosis
of diabetes, although the methods for determining HbA1c were technically demanding, time
consuming and expensive at the time [135].  Later as the instrumentation had improved, studies
were performed on estimating the stability and optimal preservation of the PM samples to attain
reliable results [136- 138 ]. HbA1c has been confirmed as a reliable PM marker for long term
hyperglycemia, and it is used for estimating the glycemic status in diabetic deaths and also for
distinguishing ketoacidosis caused by diabetes from other possible reasons [139-141].
Fructosamine is formed when blood proteins are glycated non-enzymatically as HbA1c, although
the formation is faster reflecting the glycemic control of the previous 10-20 days [142].
Fructosamines have also been evaluated in PM context for estimation of glycemic disturbances.
John et al. measured fructosamine in PM plasma with a colorimetric method from 26 non-
diabetics and 3 diabetics [143]. The high total protein concentrations of the PM samples compared
to clinical samples required a correction to the results. After correction, they found higher
fructosamine concentrations in diabetics, although the sample set was relatively small. Osuna et
al. evaluated fructosamine concentrations in VH with a colorimetric assay [144]. They analyzed
the samples of 49 diabetics and 43 non-diabetics and found fructosamine levels to be significantly
higher in diabetics. In a later study by Osuna et al. the fructosamine levels were compared to
glucose and lactate and a significant correlation was detected between glucose and fructosamine
[145]. Hess at al. presented 6 cases of hyperglycemic deaths, where fructosamine from VH, CF
and blood was measured in addition to glucose, lactate, ketones, HbA1c and 1,5-anhydroglucitol
(1,5-AG). Contrary to Osuna et al. [144], they did not detect significant differences between
diabetics and non-diabetics when VH or CF was analyzed. When blood samples were used, a
difference between these groups was seen. Their conclusion was that fructosamine can provide
additional information, but the essential markers for hyperglycemic disturbances are glucose and
ketones.
 1,5-AG is a monosaccharide naturally occurring in many foods. It competes with glucose in renal
reabsorption resulting in lower serum concentration in hyperglycemia [146]. Hess et al. have
measured 1,5-AG from PM samples [9,112]. They concluded that 1,5-AG is stable in PM samples
and the concentrations are similar in PM and clinical samples. However, although the 1,5-AG
reflects the glycemic control in a shorter period of time than HbA1c or fructosamine, it did not
correlate with glucose levels in VH. They suggested that 1,5-AG can be used as an additional
marker with VH glucose.
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2.2 Analysis of PM samples to reveal DKA and AKA
Elevated ketones are readily analyzed from PM samples. Ketone body levels are fairly stable even
if advanced PM changes have occurred [19,147] allowing the ketoacidosis to be reliably
diagnosed. The causes for ketoacidosis need additional analyses. As diabetes and alcohol abuse
are the most common causes for ketoacidosis, glycemic status is important to distinguish between
these two. In clinical medicine, a history of diabetes or alcoholism and blood glucose levels are
the significant factors, as differences in hormonal levels and metabolites other than glucose are
either not significantly diverse or cannot be readily analyzed in a timely manner [93]. DKA is
commonly associated with hyperglycemia, but some exceptions exist. Glucose levels may be
relatively low in DKA as a result of reduced gluconeogenesis caused by e.g. alcohol or liver
failure, or if food intake is reduced and/or insulin received [148,149]. In addition, as the glucose
level is decreased in the early PM phase due to glycolysis [5], the vitreous glucose may not always
be elevated in DKA related deaths. Therefore, the measurement of HbA1c provides additional
information when estimating the cause for ketoacidosis [136].
DKA can be diagnosed by analyzing the vitreous glucose and ketone bodies in VH or blood [8].
Péclet et al. found blood acetone measurements valuable in addition to vitreous glucose and
lactate in determining diabetic disturbances as the CoD. In ketoacidosis due to AKA, DKA,
malnutrition or hypothermia, the ketone body measurements of different fluids have been
described by several authors [16-19,141,150-156]. Total ketones have been analyzed from blood
and also the correlation of blood to VH, spinal fluid and urine have been evaluated [16,151,152].
The analysis of BHB has been described in PM blood, serum, VH, urine, cerebrospinal and
pericardial fluids, liver homogenate and synovial fluid [19,141,150,153,155-158]. In addition,
acetone measurements in PM blood [17] and VH [159] have been described.
2.3 PM analysis of C-reactive protein
C-reactive protein (CRP) is an acute phase protein synthetized in liver in infection, inflammation
and trauma [160]. The CRP levels of PM blood have been assessed in sepsis and non-septic
fatalities [11] and it was shown that the CRP levels in early PM phase decreased log-linearly up
to 140 hours PM. In another study the correspondence of AM and PM levels of CRP were
evaluated by analyzing 26 samples where CRP was measured at 24 hours prior to death and 1-6
days PM. In this study the average reduction of PM levels compared to AM was 35-42%
depending on the method used [161]. CRP levels have been analyzed in PM blood with emphasis
on the CoD and survival time in traumatic deaths [162]. In traumatic deaths the CRP reflected
the survival time and to some extent the severity of the tissue injury. In addition, the CRP could
be used as in clinical medicine to evaluate possible infection. The routine use of CRP
measurements of blood, serum and liver samples in CoD investigations has been assessed [12].
In the study, no significant correlation was found between PMI and CRP levels. It was also found
that CRP levels were stable in blood and serum samples for at least one month or in liver samples
for one week when stored in +5ºC. Two cases of AKA were identified with elevated CRP levels.
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No other reason than acidosis was found that could cause the elevation of the CRP. The elevation
of CRP had previously been described in DKA even in the absence of concomitant infection
[163,164], but not in AKA.
2.4 Lactate measurement and interpretation of results of PM samples
The lactate concentration of vitreous has mainly been used in evaluation of PM glycemic balance
[3,4,6,165]. In addition, Sturner et al. analyzed the lactate levels to evaluate any differences in
traumatic asphyxic deaths of infants from sudden infant death syndrome [166]. Their conclusion
was that the lactate level is lower in traumatic asphyxia where the agonal period is shorter. The
effect of prolonged agony on lactate levels was also shown by De Letter et al. [122]. In clinical
medicine, the definition of lactic acidosis may vary, but most accepted definition for diagnosis is
when the lactate level exceeds 5-6 mM and the pH of blood is less than 7.35 [94,167]. In PM
samples, the lactate levels elevate as the PMI increases causing difficulty in evaluation of the AM
lactate levels and possible lactic acidosis [168]. Therefore, careful evaluation is needed in the
interpretation of the results. Issues to be considered in addition to findings in autopsy are the PMI
and PM conditions, manner of death and medical history prior to death [169].
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AIMS OF THE STUDY
The aims of the study were:
1. to assess the combined sum of glucose and lactate as an indicator of disturbances in
glycemic control (I, V)
2. to estimate and optimize the methods for measurement of glycated hemoglobin (HbA1c)
in postmortem (PM) samples and to assess the information provided by the analysis (II,
III)
3. to evaluate ketone body levels in deaths attributed to diabetes and alcohol abuse and to
evaluate the most appropriate analysis method to determine ketoacidosis (I)
4. to measure C-reactive protein (CRP) in PM samples and to assess the role of CRP in
ketoacidosis (IV)
5. to evaluate different AM and PM factors that influence the lactate levels in PM samples
and to estimate the role of elevated lactate in diabetes related deaths (I, V)
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MATERIALS AND METHODS
1. Samples
VH and blood samples were collected in medico-legal autopsies performed at the Department of
Forensic Medicine, University of Helsinki, Finland. Autopsies were performed with a
standardized procedure and the CoD was determined by a medico-legal pathologist. The study
was approved by the HUCH Ethical Committee, the National Institute of Health and Welfare,
and the National Supervisory Authority for Welfare and Health.
According to Finnish law (Act 1.6.1973/459), the police may order a medico-legal autopsy as a
part of the CoD investigation under following circumstances:
1. if the deceased has died from an unknown disease or did not receive medical treatment
during the person’s last illness or the death has occurred under medical treatment,
2. if the death was or was suspected to be the result of an accident, criminal offence,
suicide, intoxication or occupational disease,
3. if the death was otherwise unexpected.
2. Autopsy data
Data was collected from the autopsy records of the National Institute of Health and Welfare and
from the Laboratory Information Management Software (LIMS) used at the Unit of Forensic
Chemistry in the Department of Forensic Medicine, University of Helsinki, Finland.
3. Statistical methods
IBM SPSS Statistics 21 (International Business Machines Corp., USA) and Microsoft Excel
(Microsoft Corp., USA) software were used for data management and statistics. Pearson’s chi-
squared test was used to evaluate the statistical significance in study IV.  Pearson’s correlation
was calculated for linear correlations in studies II, III and IV. Kendall’s tau correlation
coefficient was calculated to assess associations between groups in study V. The agreement
between methods was evaluated by using the Bland-Altman plot in study III.
4. Glucose and lactate measurements
Glucose was measured from perchloric acid (PCA) precipitated VH samples with the
hexokinase/glucose-6-phosphate dehydrogenase method. Glucose in the sample is
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phosphorylated to glucose-6- phosphate (G6P) by hexokinase. G6P is then further oxidized with
concurrent reduction of cofactor NADP to NADPH. The amount of NADPH is detected as a
change in absorption of light at 340 nm wavelength and it is directly proportional to the amount
of glucose in the sample. The upper reference limit for PM samples was 7 mM.
Lactate was measured from PCA precipitated VH with the LDH assay. Depending on the isoform
(L-lactate or D-lactate) quantitated, either L-LDH or D-LDH was used. L-lactate is the
predominant isoform, and is denoted as “lactate”, whereas the D-isoform is denoted as “D-
lactate” later in the text.  Lactate is oxidized to pyruvate by LDH with concurrent reduction of
cofactor NAD+ to NADH. The amount of NADH is detected as a change in absorption of light at
340 nm wavelength. Pyruvate is further incorporated to a reaction catalyzed by glutamate-
pyruvate transaminase to ensure the proceeding of the first reaction. The amount of NADH is
directly proportional to the amount of lactate in the sample. The upper reference limit for L-
lactate was 35 mM and for D-lactate 3 mM.
5. Ketone body measurements
Ketone bodies were analyzed with gas chromatography (GC). The sample material was PCA
precipitated VH or blood. First the BHB in the samples is transformed to AcAc enzymatically by
adding BHBD (Roche, Switzerland). After this the AcAc in the samples is transformed to acetone
by decarboxylation achieved by boiling the samples for 1 hour. The acetone is then analyzed with
the GC using an Elite-BAC 1 column (Perkin Elmer, USA) and the amount consists of the total
ketones in the sample. Values exceeding 1 mM indicated ketosis and 3 mM ketoacidosis.
BHB alone was analyzed enzymatically with the BHBD/diaphorase method, adapted from
methods described by Laun et al. [170] and McMurray et al. [171]. The BHB in the sample is
transformed to AcAc by BHBD in the presence of cofactor NAD+ which is reduced to NADH.
The NADH is further oxidized by diaphorase sigma-Aldrich, USA) with concomitant reduction
of iodonitrotetrazolium chloride (INT; Sigma-Aldrich, USA) to formazan. The amount of
formazan is directly proportional to the amount of BHB and can be measured with the change in
absorption of light at a wavelength of 505 nm.
6. Methods for analyzing glycated hemoglobin
HbA1c was analyzed from peripheral blood samples stored either in sodium fluoride or EDTA.
The methods used were the following:
Mono S 5/50 GL cation exchange column (GE Healthcare Europe GmbH, Germany)
using Agilent 1100 HPLC machinery and ChemStation software (Agilent Technologies,
USA)
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BioRad In2it® point-of-care analyzer, the boronate affinity method (Bio-Rad
Laboratories Ltd., USA)
Diazyme Direct Enzymatic HbA1c Assay™ (Diazyme Europe GmbH, Germany)
BioRad D-10 HPLC analyzer, the cation exchange method (Bio-Rad Laboratories Ltd.,
USA)
The reference range for PM samples was 20-67 mmol/mol. The measurements with BioRad
In2it® point-of-care and BioRad D-10 HPLC analyzer were performed as instructed by the
manufacturer. The Diazyme Direct Enzymatic HbA1c Assay™ was adapted for a microplate
according to Penttilä et al. [172]. The Mono S cation exchange HPLC method was modified from
the method described by Jeppsson et al. [173]. Briefly, the erythrocytes in whole blood were
washed with 0.9% NaCl and centrifuged. After washing the erythrocytes were disrupted with
citrate-phosphate hemolysis buffer including Triton-X. The labile intermediate form of HbA1c
was eliminated by incubating the samples in hemolysis buffer for 30 minutes at +37°C. The
supernatant was cleared by centrifugation and transferred into vials for injection to the Mono S
column. Sample loading and elution was performed with 20 mM malonate buffer with a NaCl
gradient.
7. CRP measurements
CRP values of the PM samples were measured using the QuikRead 101-CRP instrument (Orion
Diagnostica Oy, Finland). The assay is an immunoturbidometric test in which the CRP in the
sample reacts with microparticles coated with anti-human CRP F(ab)2 fragments. The change in
turbidity of the solution is measured by the QuickRead Instrument photometrically. The samples
analyzed were peripheral blood samples stored in EDTA.
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RESULTS
1. Traub value in predicting glycemic disturbances (I, V)
We evaluated the Traub formula (I) by assessing 70 cases where the CoD was DM (insulin
dependent, non-insulin dependent or other/unspecified). Among the 70 cases there were 12 cases
where the CoD was specified to be hyperglycemic coma due to diabetes and 31 cases with
diabetes-caused ketoacidosis as CoD. In two of the hyperglycemic coma cases glucose levels did
not exceed the 7 mM threshold indicating hyperglycemia, but in both cases the Traub value
exceeded 35 mM. In the DKA cases, the glucose was elevated in 19 of the 31 cases and the Traub
value in 27 cases. Glucose level was elevated in 54.3% and the Traub value in 85.7% of the 70
cases. When cases other than DM related deaths were assessed (N = 910) glucose was elevated
in 7.1% of the cases and the Traub value in 35.9% of the cases. Ketone bodies were elevated in
all DM related cases (N = 70).
For assessing the glucose and lactate levels in relation to PMI, 1865 cases were evaluated where
the PMI was 1-10 days (V) The average glucose level for all cases was 1.9 mM and lactate level
32.0 mM, so both the lactate level and the Traub value remained under the previously defined 35
mM threshold. The relations of glucose and lactate levels to PMI evaluated in 1865 cases are
presented in Figures 3a and 3b. The glucose is fairly stable PM. Lactate on the contrary elevates
rapidly approximately up to 4 days PM, after which the elevation slows and a plateau is reached
around 8-10 days PM.
Figure 3a Glucose levels in relation to PMI
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Figure 3b Lactate levels in relation to PMI
The following subgroups from the 1865 cases evaluated were formed based on the CoD; DM1,
DM2 and metformin poisoning.  The mean glucose and lactate levels for all cases and for these
subgroups at the 95% confidence interval (± standard error, SE) are presented in Table 2.
Table 2 Mean glucose and lactate levels in PM samples
Cause of death Glucose (mM) ± SE of
mean
Lactate (mM) ± SE of
mean
All cases (N = 1865) 1.9 ± 0.1 32.0 ± 0.2
Diabetes mellitus type 1 (N = 32) 17.5 ± 1.8 32.0 ± 1.3
Diabetes mellitus type 2 (N = 41) 8.3 ± 1.3 37.2 ± 1.2
Metformin poisoning (N = 9) 1.3 ± 0.7 36.8 ± 2.6
To reduce the effect of the PMI, lactate values for the subgroups were normalized against the
mean value for the particular PMI in all cases (Fig. 3b). In the DM1group the normalized value
was 0.98, in the DM2 group 1.13 and in the metformin group 1.16
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2. HbA1c methods in PM sample analysis (II, III)
Three different methods were evaluated for measurement of HbA1c in 20 PM samples (II). The
methods compared were cation exchange chromatography (Mono S HPLC), an enzymatic
method (Diazyme Direct Enzymatic HbA1c Assay™) and a POC method based on boronate
affinity (BioRad In2it®). The Mono S HPLC was the reference method used previously in the
laboratory. The correlations of the enzymatic method and the boronate affinity method compared
to cation exchange HPLC were R2 = 0.68 and R2 = 0.84, respectively. Mono S HPLC gave results
for all the samples but one where the deceased had been embalmed. The other two methods gave
a false result for the embalmed sample. In addition, the boronate affinity and enzymatic assay
failed to give a result in 5 cases due to PM deterioration of the samples.
We compared the Mono S HPLC to a fully-automated BioRad D-10 analyzer that was also based
on cation exchange chromatography (III).  A set of 71 samples were analyzed in parallel with
both assays, in which 3 of the samples were clinical and 68 PM blood samples. Both of the
methods failed to give a result for three samples; one of the cases was embalmed, another in an
advanced decomposition state and in the last case the proportion of fetal hemoglobin (HbF)
exceeded 10%. The Mono S HPLC method did not give a result for four other samples due to
sample decomposition. Correlation coefficient of the BioRad D-10 HPLC compared to Mono S
HPLC was R2 = 0.91. The agreement of the two methods was evaluated by using the Bland-
Altman plot [174,175] after taking a natural logarithm (ln) of the measurements and performing
a linear regression analysis. After the ln transformation and linear regression, the limits of
agreement were reasonably narrow (Equation 1) and the results attained with the BioRad D-10
HPLC analyzer were comparable to Mono S HPLC results, especially in higher mean levels close
to the 67 mmol/mol reference limit.
Equation 1. ln (difference, mmol/mol) = -0.141 x ln (result, mmol/mol) + (0.584±0.386)
3. PM sample storage for HbA1c analysis with Mono S HPLC (II)
To evaluate the optimal storage and preservation the PM blood samples were stored in sodium
fluoride (NaF) or ethylenediaminetetraacetic acid (EDTA). The storage temperature was +4°C
and aliquots of the samples were frozen at -70ºC for evaluation of the effect of the freeze-thaw
cycle. The correlation of 37 frozen and +4ºC stored sample results was R2 = 0.86. EDTA and NaF
were compared as preservatives by measuring 10 parallel samples at 1 day, 1 week and 4 weeks
after sampling. All samples were stored at +4ºC. EDTA proved to be the optimal preservative
compared to NaF, as the HbA1c levels in EDTA samples were higher even in the first
measurement after 1 day (Figure 4).  The correlation was good for EDTA samples after one week
(R2 = 0.96) and even after four weeks (R2 = 0.91). NaF sample values showed markedly weaker
correlation after 1 week (R2 = 0.66) and no correlation was seen after 4 weeks of storage.
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Figure 4 The effect of NaF and EDTA to HbA1c levels of 10 PM samples
4. Ketone body levels in DKA and AKA (I)
Ketone bodies (total ketones) of 980 cases were evaluated in context of the CoD. Ketones were
elevated in 29% of the cases. When grouped into diabetes (N = 53), alcohol abuse (N = 73) and
both diabetes and alcohol abuse (N = 33) related deaths, the ketones were elevated in 78%, 54%
and 71% of the cases, respectively. The mean ketone body level in alcohol abuse related deaths
was 6.5 mM (median 1.2 mM). In diabetic deaths and alcohol abuse combined with diabetes the
mean levels were higher; 18.2 mM (median 10.0 mM) and 15.8 mM (median 6.3 mM),
respectively.
5. BHB values compared to total ketones and acetone (I)
For comparison of BHB to total ketone levels and acetone, 36 samples were chosen with normal
total ketone levels as controls and 25 samples where total ketones were elevated. The sensitivity
of the BHB assay was 84% for predicting ketosis (  1 mM) and 100% for predicting ketoacidosis
(  3 mM). The specificity was 88.9% for ketosis and 100% for ketoacidosis. Acetone alone was
detected in 8 out of 12 cases where total ketones indicated ketoacidosis.
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6. Ketoacidosis and CRP (IV)
For the evaluation CRP measurement of PM samples 41 cases were chosen where AM values of
CRP were known. AM CRP analyses were performed less than 24 hours prior to death. CRP was
found to reflect the AM state the PM value being approximately 42% of the AM value. CRP was
also very stable in samples stored at +5ºC for even up to 75 days. The longest PMI of the samples
analyzed in the study was 18 days.
To assess the relationship of CRP and ketoacidosis, 114 cases were chosen with a known alcohol
abuse history. Of the 114 samples analyzed for glucose, lactate, ketone bodies and CRP there
were 11 cases where the cause of elevated CRP was most likely ketoacidosis. In 4 of the 11 cases
the deceased was diabetic, the remaining 7 had AKA. In all of the 11 cases hepatic steatosis and/or
incipient liver cirrhosis was detected. The influence of these conditions on CRP was evaluated
with another sample set of 17 cases without ketosis. In 3 of the 17 cases the CRP was elevated
where one of these could be explained by pulmonary embolism
7. Correlation of lactate to metformin, blood alcohol concentration, metabolic
markers and PMI (V)
Kendall’s tau correlation was calculated for 319 PM samples of DM2 patients where metabolic
markers (Glucose, lactate and ketone bodies), blood alcohol concentration (BAC) and metformin
were analyzed. Lactate correlated with glucose, ketone bodies, metformin and PMI at the
significance level p = 0.01 and with BAC at the significance level p = 0.05. In addition to lactate,
metformin correlated with ketone bodies (p = 0.01). The mean lactate level in the cases (N = 59)
where no metformin was detected was 37.8 ± 1.9 mM (95% CI, SE) and ketone body level 3.7 ±
2.1 mM. In the remaining 260 cases the mean metformin concentration was 17.2 ± 3.8 mg/l and
range 1-280 mg/l, lactate level 37.4 ± 0.9 mM and ketone body level 2.8 ± 0.7 mM.
8. D-lactate levels of PM samples (V)
D-lactate was measured from 69 VH samples. Average D-lactate level was 0.42 mM ± 0.78 mM.
No correlation of vitreous D-lactate to L-lactate, glucose or ketones was detected. PMI and D-
lactate had a minor positive correlation (R2 = 0.13) that was not statistically significant. In two
samples the D-lactate concentration exceeded the 3 mM threshold. In the first case the deceased
did not have diabetes and the VH sample was visibly putrefied. L-lactate was 35.7 mM, glucose
1.9 mM, ketones 0.71 mM and D-lactate 5.4 mM. In the second case the VH sample was not
visibly deteriorated and the deceased was known to have DM1. L-lactate was 47.1 mM, glucose
13.6 mM, ketones 0.21 mM and D-lactate 3.5 mM.
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DISCUSSION
1. Evaluation of the Traub value (I)
The Traub value [120] of PM samples has been used routinely in estimations of hyperglycemia
prior to death [3,4,6,121,176]. Zilg et al. [5] analyzed glucose, lactate, potassium, sodium and
chloride concentrations of 3076 PM samples. Their conclusion was that only vitreous glucose
should be used for estimating severe AM hyperglycemia that could have caused or contributed to
death. The conclusion was based on the continuous PM elevation of lactate, whereas the glucose
drop is limited to the early PM phase after which the concentration is relatively stable.
Hyperglycemic coma cases where only lactate would have been elevated without elevated
glucose were not detected in their study. Palmiere et al. analyzed 470 cases to evaluate the
accuracy of the Traub value [123]. Glucose, lactate, BHB, acetone and HbA1c were measured to
determine possible fatal DKA. They found 11 cases where the glucose level exceeded 10 mM
and in 8 of the cases the CoD was DKA. If the Traub sum had been used, the results would have
falsely indicated glycemic disturbance in 15 cases. Their conclusion was that the Traub sum
consists mainly of glucose in cases of glycemic disturbances and of lactate in other causes. Hess
et al. [112] came to the same conclusion in their study, in which glucose, lactate, ketone bodies,
HbA1c and 1,5- AG were analyzed. In a comparison of 80 cases the correlation of glucose in VH
and CSF was good (R2 = 0.922), whereas the addition of lactate values lowered it (R2 = 0.815)
showing that the concentrations of glucose and lactate are influenced differently after death.
In our study (I) we analyzed the glucose, lactate and ketone body levels of 980 PM samples. In
70 of the cases, the death was caused by complications of DM. In these 70 cases, the CoD was
DKA in 31 of the cases and diabetic coma in 12 of the cases. Glucose was elevated (  7 mM) in
10 of the 12 diabetic coma cases and the Traub sum in all 12 cases. In the DKA cases, the glucose
level was elevated in 19 of the 31 cases and the Traub sum in 27 of the 31 cases. In the diabetic
coma and DKA cases glucose would be expected to be elevated in all cases. However, our results
are partly controversial compared to studies where glucose alone can be used for diagnosing AM
hyperglycemia. One explanation could have been the relatively long PMI of the cases in our
study; the mean time from the death to the arrival of the samples in our laboratory was 7 days in
2011 when the study was performed. The PMI in the study by Zilg et al. was less than 4 days and
in the study by Palmiere et al. VH and CF samples were collected within 12 hours from the death.
In our study, the Traub value was elevated more often in diabetics (85.7%, N = 70) than in cases
where the CoD was not related to DM (35.9%, N = 910). For these reasons, we concluded that in
cases of long PMI the Traub sum should be taken into consideration when glycemic disturbances
are suspected and when it is elevated, other additional biomarkers such as HbA1c and ketone
bodies should be analyzed. The diabetic coma in DM1 and DM2 (ICD-10; E10.01 and E11.01)
is defined as “hyperglycemic coma”, although the diagnosis includes ketoacidotic coma. If the
presence of ketoacidosis is not additionally stated, any retrospective study based on CoD coding
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information will have problems in distinguishing between HHS and DKA from only the
laboratory data.
2. Lactate levels and interpretation of the results (I, V)
As can be seen from Figure 3b, the lactate levels are elevated in a logarithmic manner in the first
days PM after which the elevation slows and a plateau is reached around 8-10 days PM. This
reminds very much of a bacterial growth curve. Although the VH is better conserved than blood
in cadavers, some bacterial contamination exists especially after longer PMIs.  Brzeziñski and
Godlewski [177] studied pig eyeballs stored in +6-8ºC and sampled sequentially from 4 to 148
hours PM. No bacteria were detected in VH smears of samples where the PMI was less than 76
hours, but after 124 hours all the smears contained mainly gram-negative bacteria. At optimal
temperatures the growth would probably be detected even earlier. This effect of bacterial
metabolism as PMI increases causes difficulties in predicting the results. Therefore, we concluded
that the lactate levels could be more informative if they are compared to reference levels defined
for different PMIs. This could give a more reliable estimation of possible AM lactic acidosis than
comparing all the results to a fixed value. Some uncertainty still remains even when a
comprehensive reference set with known PMIs is used, since the PMI is an approximation in
about half of the cases routinely analyzed in our institution. In addition, the bacterial growth may
be different due to environmental factors, such as temperature and surroundings as well as
pathological conditions or inter-individual diversities of microbiomes [178-180].
 In our earlier study (I) we found that the Traub value is more often elevated than glucose alone
when the CoD is diabetes related. For this reason, we evaluated the lactate levels in DM1, DM2
and metformin poisonings by normalizing to the values of 1865 cases with various CoDs and
known PMI (V). The lactate levels in DM1 were close to the levels for all cases, whereas in DM2
and metformin poisonings there was a 13-16% elevation (Table 2). This could explain the
correlation of the Traub value and glycemic disturbances in DM2. In DM1 the glucose level is
markedly higher (17.5 mM) than in all the cases (1.9 mM) and also in DM2 (8.3 mM), which
elevates the sum of glucose and lactate. Although the Traub sum is indicative of glycemic
disturbance, we concluded that it should be omitted and the interpretation of glucose and lactate
should be performed separately.
In addition to PMI, the correlation of lactate was significant at the level of p = 0.01 for glucose
ketone bodies and metformin. Ketoacidosis and lactic acidosis can be concomitant [17,181] in
both DKA and AKA, which could explain our finding. Cox et al. [181] found in their study that
lactic acidosis is common with DKA patients. They suggested that in addition to hypoperfusion,
the altered glucose metabolism in hyperglycemia and elevated counterregulatory hormones
contribute to excess lactate formation. A case report by Feenstra et al. also emphasized the
metabolic derangements in addition to hypoperfusion and hypoxia [182].  Brinkmann et al. looked
into the AKA and lactic acidosis of alcoholics [17]. The study had separate groups for both
conditions, but they found one case where the criteria for both were fulfilled. Their conclusion
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was that these conditions may exist combined and lead to fatal outcome. Umpierrez et al.
compared the metabolic profiles of DKA and AKA patients and found lactate levels to be more
elevated in AKA [93]. The probable explanation was the elevation of NADH/NAD+ ratio due to
ethanol metabolism in AKA.
The correlation of metformin to lactate and ketone bodies in 319 DM2 cases was significant at
the level of p = 0.01. It would be tempting to associate the elevated lactate levels with the use of
metformin, as it is the most described oral therapy in Finland for DM2 patients according to Kela
(The Social Insurance Institution of Finland). But when the DM2 cases were analyzed (V), the
lactate level was similar in cases where no metformin was detected (N = 59, lactate 37.8 ± 1.9
mM) than in cases where the metformin ranged from 1-280 mg/l (N = 260, lactate 37.4 ± 0.9
mM). This leads to a conclusion consistent with the Cochrane review by Salpeter et al. [99], that
DM2 and its complications rather than metformin are the cause for elevated lactate levels and
possible lactic acidosis. Metformin is eliminated by secretion of the kidneys [183] and lactate is
metabolized mainly in the liver [94]. In DM2 the metabolism in the liver is often disturbed [184]
and especially in ketosis and DKA there are functional disturbances in the liver and in kidneys
[185]. The functional problems caused by DM complications in the liver and kidneys could
explain the concomitant accumulation of metformin with lactate and/or ketone bodies. This
matter should be further evaluated with clinical sample material, where total ketones (or BHB),
lactate and metformin should be systematically analyzed and the function of the liver and kidneys
assessed, since in forensic biochemistry, the PM changes affecting the lactate concentration
causes some uncertainty to the interpretation of results. A restriction of our results is that in this
set, the actual lactate concentration was used and not values normalized to PMI-specific values,
since in almost half of the cases the PMI was an approximation.
D-lactate is elevated in the urine and plasma of diabetics compared to non-diabetics [110,111].
We analyzed 69 VH samples in a preliminary trial to assess if the D-lactate levels would provide
additional information of the metabolic status prior to death (V). No correlation to L-lactate,
glucose or ketone bodies was detected and there was only a minor correlation with PMI. Two of
the samples exceeded the 3 mM threshold, in which for one case the cause was most likely
bacterial metabolism, since the sample was visibly putrefied and there were no other factors
referring to diabetic complications. For the second case, diabetic complications might have
caused the elevation, since the deceased had DM1 and the sample was well preserved. The
measurement of D-Lactate needs further evaluation probably with a more precise assay method
then the enzymatic assay we used. Urine could be an alternative sample matrix to VH.
3. Ketoacidosis, causes and measurement (I, IV)
DKA is known to induce the expression of pro-inflammatory cytokines and CRP [163]. Gogos et
al. [186] showed in their study that 80% of 61 DKA or HHS patients had symptoms of SIRS.
Although infection is often a precipitating factor in DKA, they also showed that the CRP levels
in DKA patients with sepsis are significantly higher than in patients with SIRS with no infection.
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The mechanism when no infection is present is probably due to the oxidative stress caused by the
hyperglycemic crises [164]. Jain et al. [187] concluded in their review that in addition to
hyperglycemia, the ketone bodies cause oxidative stress as well.  The findings by Stentz et al.
[164] were similar and they concluded that hyperglycemia and ketoacidosis influence oxidative
stress and pro-inflammatory markers independently without synergistic effects. This would
suggest that ketoacidosis without hyperglycemia, as in AKA, could also elevate markers of
inflammation. Indeed, a study by Astrup and Thomsen [12] confirmed this as they found 2 cases
where CRP was elevated due to AKA. We looked into this in our study (IV) where 114 cases
were analyzed for ketone bodies and CRP. We found 11 cases where the probable cause for
elevated CRP level was ketoacidosis. Of these, 7 were diabetics but for the remaining 4 the reason
for ketoacidosis was most likely alcohol abuse. Therefore, our findings were consistent with
Astrup and Thomsen [12] and we concluded that ketoacidosis alone can elevate the CRP level.
DM and alcohol abuse may cause liver diseases [184,188] that can result in an inflammatory
response. Since in all of our 11 cases some degree of liver disease was seen, another set of 17
samples was analyzed for CRP where the deceased had fatty liver changes or liver cirrhosis, but
the ketone bodies here were under the reference limit. CRP was elevated in 3 cases and in one of
those the cause was pulmonary embolism. Our conclusion was that the CRP levels are not
markedly affected by steatohepatitis or incipient liver cirrhosis.
Ketoacidosis is most commonly caused by DM or alcohol abuse. In our study (I) we investigated
whether there are differences in the ketone body levels between these two groups and a group
where both, DM and alcohol abuse, contributed to death. Ketone body levels were lowest in the
alcohol abuse group (N = 73) the median being 1.2 mM. The groups where the CoD was diabetes
related (N = 53) or diabetes and alcohol abuse related (N = 33) the median ketone body levels
were markedly higher; median 10.0 mM and 6.3 mM, respectively.  Although the ketone body
level is lower in the alcohol abuse group, sporadic extremely high (  20 mM) values were also
detected. Our conclusion was that the ketone body level does not reflect the cause of ketoacidosis.
For differentiation between DKA and AKA additional markers, such as glucose and HbA1c, need
to be analyzed. Since glucose levels may be reduced in DKA patients e.g. after insulin intake,
reduced food intake and in the presence of impaired gluconeogenesis [149] it is essential to
measure the HbA1c in addition to glucose.
In PM context, the estimation of ketoacidosis can be performed by measuring acetone [4], BHB
[140,150] and/or total ketones [152]. Elliott et al. [189] analyzed ethanol, acetone and BHB in
350 PM cases of alcoholics, diabetics and alcoholic diabetics. Their conclusion was that acetone
can be used as an initial marker for ketoacidosis and the acetone positive cases (0.002 g/l, limit
of detection in the study) can be further analyzed for BHB. The same conclusion was made by
Hockenhull et al. [190] as their study showed that although the BHB is more precise marker, the
preliminary screening can be done by analyzing acetone. In contrast, a study by Iten and Meier
[19] found that acetone was elevated only in 64% of the cases in AKA cases where BHB was
elevated. In clinical medicine, it has been shown that acetone and acetoacetate are not necessarily
elevated even in moderate ketoacidosis and BHB should be preferred as the marker for
ketoacidosis [191]. In our study (I) BHB and acetone were analyzed from PM samples where
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total ketones had been previously measured. Based on the total ketone measurements we chose
36 samples as controls and 25 samples where the total ketones exceeded the 1 mM threshold for
ketosis. The BHB assay showed 84% sensitivity and  88.9% specificity for samples referring to
ketosis and 100% sensitivity and specificity for samples referring to ketoacidosis (  3 mM total
ketones). Acetone alone was detected in 8 out of 12 samples in which the total ketone and BHB
measurements referred to ketoacidosis. Our findings were in contrast to the conclusions by Elliott
et al. [189] and Hockenhull et al. who found [190] that acetone would be sufficient for primary
screening for ketoacidosis. Our conclusion was that either BHB or total ketones need to be
analyzed to detect ketoacidosis. The contrary results could be caused by different methodology
and/or differences in sample quality and type, since these are specific for each laboratory and
greatly influence the results and interpretation of the results.
4. Measurement and importance of HbA1c in PM samples (II,III)
We compared three different methods for HbA1c measurement of PM blood samples (II). The
reference method was based on cation exchange chromatography and the other two methods were
point-of-care (POC) assay based on boronate affinity chromatography [192] and an enzymatic
assay [193]. We noticed that in the analysis of PM samples, it is necessary to be able to visualize
the results as we can with chromatography to detect erroneous results due to PM changes, as one
sample where the deceased had been embalmed gave a false result when analyzed with the
enzymatic and POC assays. The cation exchange HPLC did not give a result and the abnormal
matrix could be detected in the chromatogram. The POC assay correlated better than the
enzymatic assay when compared to the cation exchange HPLC, but it failed to give a result in 5
out of 20 samples due to the PM deterioration of the samples. We concluded that the Mono S
cation exchange HPLC was the optimal method for the laboratory to analyze PM samples. In our
later study (III) we compared the BioRad D-10 fully-automated analyzer also based on cation
exchange HPLC to the Mono S HPLC method to improve the measurement of HbA1c in PM
samples. The correlation of the two methods was good (R2 = 0.91) as were the limits of agreement
analyzed by using the Bland-Altman method. The fully-automated analyzer was more cost-
effective and it could be used for analyzing some samples that were too deteriorated to give a
reliable result with Mono S HPLC. This was probably due to the pre-treatment needed for Mono
S HPLC that might be too harsh for already slightly deteriorated samples. Our conclusion was
that the previously validated Mono S HPLC method could be replaced with the BioRad D-10
analyzer.
PM samples are often stored in NaF to inhibit further bacterial growth and changes in the matrix
after sampling [194]. Goullé et al. [136] compared the effect of preservatives (none, NaF and
EDTA or heparin) on PM samples prior to HbA1c measurement. They found that the HbA1c
peak can be detected in NaF stored samples up to 3 months and in samples stored without a
preservative, or in EDTA or heparin, for up to one year when the storage temperature was +4ºC.
When parallel measurements of samples stored with NaF, heparin or without a preservative were
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performed they found no significant differences in the HbA1c levels. However, EDTA was the
recommended preservative. Also in a study by Winecker et al. [137] no differences were found
in parallel samples of NaF and EDTA stored blood. Our results on the contrary showed that NaF
stored samples give lower values compared to EDTA stored samples even after one day of storage
at +4ºC. After one week the NaF stored samples give markedly lower values, whereas the EDTA
stored samples are fairly stable for at least up to 4 weeks. Our conclusion was that EDTA should
be used as a preservative. If samples are stored in NaF, the results for samples frozen at -70ºC
correlate better than those for samples stored at +4ºC for at least one week. In the study of
Winecker et al. the samples used for comparison of preservatives were samples from healthy
volunteers so presumably the samples were more stable than if PM samples were used. In the
study of Goulle et al. no quantitative values were given for samples stored from 3 months up to
one year, they only determined if the HbA1c peak could still be detected.
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GENERAL DISCUSSION AND FUTURE AIMS
Aurelio Luna asked the question “Is postmortem biochemistry really useful? Why is it not used
more widely?” in his review [1]. One of the challenges in PM biochemistry is the absence of
reference values for analytes to aid in the interpretation of results. Published research can provide
some guidelines, but each laboratory needs to define the RIs specific for the samples analyzed
and for the methods used in that particular laboratory. This requires thorough research with
sufficient amounts of samples and data. In addition, the methodology needs to be optimized for
demanding sample materials. Pre-treatment of samples is often needed, which may cause
difficulties when samples are at least partially deteriorated. In the assessment of the results and
their importance, a knowledge of laboratory sciences alone is not sufficient but a knowledge of
forensic medicine is also required making PM biochemistry a multidisciplinary scientific field.
In addition, the results on their own are not of any value, but they need to be incorporated as part
of all the other findings in CoD investigations [8].
Glycemic disturbances are difficult to diagnose in autopsy or histology alone, this is why
biochemical methods are needed for additional information [6,37,195]. Hyperglycemia was long
evaluated by analyzing glucose and the Traub sum where glucose and lactate are combined
[3,4,6,121]. The Traub sum seemed to exaggerate the number of hyperglycemic deaths and after
further research the conclusion by many is that it should be omitted [5,112,123]. In our research
we found it to correlate with diabetic deaths (I) and concluded that a relatively long PMI in our
institution may be one factor for our results diverting from those of others. However, after our
later study (V) it seems that in DM1 glucose alone is more informative and the elevation of the
Traub sum in DM2 is caused by metabolic impairment of the disease and not directly due to
hyperglycemia. The importance of lactate in assessing glycemic disturbances needs further
evaluation by using PMI-specific reference values. It would also be informative to include
samples from medical autopsies where more often results from recent AM laboratory assays are
obtained, which is rarely the situation in forensic autopsies.
Hypoglycemia still remains unidentified by biochemical means from PM samples. Low values of
the Traub sum have been suggested to indicate hypoglycemia [3], but according to our study V it
is evident that lactate levels are affected mainly by the microbial metabolism associated with PMI
and glucose is very low even in normoglycemic cases. Therefore, the Traub sum is not reliable
for diagnosis of hypoglycemia. In addition to insulin detection, hypoglycemia could be detected
by means other than direct metabolite concentrations. Sharp et al. showed in their animal study,
that a distinct gene expression profiles can be detected in ischemic and hemorrhagic stroke,
hypoxia, and hypoglycemia [196]. The challenge in analyzing RNA levels as with other
biological markers is the PMI related degradation. Blood may not be the optimal matrix [197],
but for instance RNA in brain tissue could be more stable [198].
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Glycemic balance in previous weeks can be evaluated by analyzing the HbA1c levels. HbA1c is
readily measured from PM samples, although the methodology and sample preservation need to
be optimized, as was shown in our studies II and III. HbA1c level reflects the long term glycemic
balance and does not reveal the immediate blood glucose level prior to death, this is why it is not
always seen as obligatory but more as an optional analyte [112]. Regardless of this, the
information provided by HbA1c levels of PM samples in forensic medicine is significant when
evaluating the causes for ketoacidosis, the glycemic balance of diabetics or possible undiagnosed
diabetes. Therefore, in our opinion it should be included when assessing possible glycemic or
acidotic disturbances.
DKA is a known complication of DM but AKA is often undiagnosed [81]. Analysis of ketone
bodies in PM blood or VH is essential when metabolic disturbances due to diabetes or alcohol
are suspected. Acetone is often measured in the analysis of alcohols. However, in our study I it
was shown that acetone alone is not sufficient, but either total ketones or BHB need to be analyzed
for the diagnosis of ketoacidosis. In our study IV we could confirm the finding of Astrup et al.
[12] that CRP is elevated AKA. The inflammatory reaction had been described earlier in DKA
[163,164] and it is suggested to associate with severe complications of DKA [199]. The
association of CRP and AKA could be further assessed by including the analysis of cytokines.
This could provide more information on the pathophysiology of AKA.
In our research (I-V) we have focused on the metabolic aspects in DM and alcohol abuse related
deaths. Our results and findings have enabled the Laboratory of Forensic Biology to improve and
adapt the methods as well as interpretations of the results used in routine casework. With
continuous research and development of new methods PM biochemistry can provide important
information for the medico-legal pathologists. It is easy to agree with the reply of Aurelio Luna
to his question of the importance of PM biochemistry: “I think that the biochemical methods must
be integrated in the autopsy routine with precautions in the fields with inconclusive data but with
trust in the fields where the data are conclusive”.
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CONCLUSIONS
Ketoacidosis can be detected by the quantitation of either BHB or total ketones in PM samples.
To define the cause for ketoacidosis, additional markers such as glucose and HbA1c need to be
analyzed. HbA1c is a reliable marker for poor glycemic control or undiagnosed diabetes and it
can be used for distinguishing DKA from AKA. CRP level may be elevated in DKA and AKA
without a concurrent infection. The elevation can be explained by the oxidative stress and
following inflammatory state caused by hyperglycemia and/or hyperketonemia. The lactate levels
of PM samples are relatively high due to PM changes and microbial metabolism. To evaluate any
possible AM lactic acidosis, PMI-specific reference values may be more informative than a fixed
value. Lactic acidosis is often caused by metabolic disturbances in DM and alcohol abuse.
According to our studies of PM samples, the association between metformin and elevated lactate
levels seems more likely to be concurrent than causal. For the assessment of metabolic
disturbances, measurement of glucose, ketone bodies and HbA1c in PM samples is needed, while
the information provided by lactate levels requires further evaluation. These markers should be
analyzed in all cases where a death is caused or related to DM or alcohol abuse and also in cases
where these conditions are not suspected, but there are few findings following autopsy.
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